Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 8/20 | 0.60 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.59 |
| ▸ | YARS1 | P54577 | 2/20 | 0.56 |
| ▸ | ACE | P12821 | 2/20 | 0.52 |
| ▸ | CPA1 | P15085 | 1/20 | 0.52 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.52 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30326195 | 1.00 | MME (0.60) | MMESLC7A5YARS1ACECPA1 | |
| SCHEMBL7149290 | 1.00 | MME (0.60) | MMESLC7A5YARS1ACECPA1 | |
| SCHEMBL30287990 | 0.96 | MME (0.60) | MMESLC7A5YARS1ACECPA1 | |
| SCHEMBL30287993 | 0.96 | MME (0.60) | MMESLC7A5YARS1ACECPA1 | |
| SCHEMBL31025679 | 0.96 | MME (0.60) | MMESLC7A5YARS1ACECPA1 | |
| Water SCHEMBL7150501 | 0.96 | MME (0.56) | MMESLC7A5YARS1ACECPA1 | |
| SCHEMBL30788342 | 0.94 | MME (0.54) | MMESLC7A5YARS1ACECPA1 | |
| SCHEMBL30288033 | 0.92 | MME (0.66) | MMEACEOPRD1 | |
| SCHEMBL30288011 | 0.92 | MME (0.66) | MMEACEOPRD1 | |
| SCHEMBL30288043 | 0.92 | MME (0.66) | MMEACEOPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114984255-A | Radionuclide-labeled PSMA-alpha v beta 3 double-target couplet and application thereof | 苏州大学 | 2022-09-02 | — | — | CN | claimed |
| CN-105407907-A | Uric acid level lowering agent | SUNTORY HOLDINGS LTD | 2016-03-16 | — | — | CN | claimed |
| US-20260110003-A1 | COMPOSITIONS AND METHODS FOR PRODUCTION OF HIGH VALUE CHEMICALS FROM ETHANOL | SOLUGEN, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| US-12570729-B2 | Antibody fragment based antifungal conjugate selectively targeting candida | ABGENICS LIFESCIENCES PRIVATE LIMITED (IN) | 2026-03-10 | — | — | US | disclosed |
| EP-4634396-A1 | BIOBASED SYNTHESIS OF GLUCODIAMINE | Solugen, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| WO-2025076549-A1 | SMALL MOLECULE ACTIVATORS | SOLUGEN, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| CN-119015278-B | Cymosine-polypeptide coupled compound, and preparation method and application thereof | 广州医科大学 | 2025-03-14 | — | — | CN | disclosed |
| CN-119015278-A | Novel use of cytisine, cytisine-polypeptide coupled compound, preparation method and use thereof | 广州医科大学 | 2024-11-26 | — | — | CN | disclosed |
| US-20240368642-A1 | COMPOSITIONS AND METHODS FOR PRODUCTION OF VALUE-ADDED CHEMICALS | SOLUGEN, INC. (US) | 2024-11-07 | — | — | US | disclosed |
| WO-2024227189-A2 | BIOBASED POLYESTERS AND METHODS OF MAKING AND USING SAME | SOLUGEN, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| WO-2024129887-A1 | BIOBASED SYNTHESIS OF GLUCODIAMINE | SOLUGEN, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| EP-0457701-B1 | Derivatives of endogenous mediators, their salts, process for preparation, application and compositions containing them | IMMUNOTECH SA (FR) | 1995-02-22 | — | — | EP | disclosed |
| US-5298491-A | Derivatives of endogenous mediators, their salts, method of preparation, applications and compositions in which they are present | IMMUNOTECH (FR) | 1994-03-29 | — | — | US | disclosed |
| EP-0278787-B1 | A process for enzymatic production of dipeptides | CARLBIOTECH LTD AS (DK) | 1993-10-20 | — | — | EP | disclosed |
| EP-0457701-A1 | Derivatives of endogenous mediators, their salts, process for preparation, application and compositions containing them | IMMUNOTECH S.A. (FR) | 1991-11-21 | — | — | EP | disclosed |
| EP-0145386-B1 | DERIVATIZED POLYSTYRENE AND OTHER POLYMER SUPPORTS FOR SPECTROSCOPIC STUDIES | CITY OF HOPE NATIONAL MEDICAL CENTER (US) | 1991-05-15 | — | — | EP | disclosed |
| US-4978724-A | Method of preparing derivatized polystyrene for spectroscopic studies | APPLIED IMMUNESCIENCES, INC. (US) | 1990-12-18 | — | — | US | disclosed |
| WO-1988006187-A1 | A PROCESS FOR ENZYMATIC PRODUCTION PRODUCTION OF DIPEPTIDES | CARLSBERG BIOTECHNOLOGY LTD. A/S (DK) | 1988-08-25 | — | — | WO | disclosed |
| EP-0278787-A1 | A process for enzymatic production of dipeptides | CARLBIOTECH LTD. A/S (DK) | 1988-08-17 | — | — | EP | disclosed |
| EP-0145386-A2 | Derivatized polystyrene and other polymer supports for spectroscopic studies | CITY OF HOPE NATIONAL MEDICAL CENTER (US) | 1985-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570729-B2 | Antibody fragment based antifungal conjugate selectively targeting candida | SERPINH1, HM13, NGLY1 | MME 50/4885SLC7A5 2455/4885YARS1 2111/4885 |
| US-20260110003-A1 | COMPOSITIONS AND METHODS FOR PRODUCTION OF HIGH VALUE CHEMICALS FROM ETHANOL | ADH1A, ADH1C, PC | MME 4411/4885SLC7A5 3342/4885YARS1 2106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.